Broncus Holding Temettü

Temettü kriter kontrolleri 0/6

Broncus Holding şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	3.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-HK$0.04
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Dec 06

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

Sep 04

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Jun 21

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 2216 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 2216 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Broncus Holding Piyasaya Karşı Temettü Getirisi

2216 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (2216)	n/a
Pazarın Alt %25'i (HK)	3.2%
Pazarın En İyi %25'i (HK)	7.9%
Sektör Ortalaması (Medical Equipment)	3.3%
Analist tahmini (2216) (3 yıla kadar)	0%

Önemli Temettü: 2216 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 2216 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 2216 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 2216 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Broncus Holding Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

First half 2024 earnings released: US$0.016 loss per share (vs US$0.03 loss in 1H 2023)

Broncus Holding Corporation to Report Q2, 2024 Results on Aug 29, 2024

Broncus Holding Corporation Announces Management Changes

Broncus Holding Corporation Announces Changes to Its Board

Full year 2023 earnings: EPS and revenues miss analyst expectations

Broncus Holding Corporation, Annual General Meeting, May 20, 2024

We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Broncus Holding Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

Broncus Holding Corporation Announces Resignation of Zhenjun Zi as Non-Executive Director

Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Broncus Holding Corporation (SEHK:2216) entered into share purchase agreement to acquire Fibernova Holding Corporation from from Zhao and others for $2.7 million.

First half 2023 earnings released: US$0.03 loss per share (vs US$0.033 loss in 1H 2022)

Broncus Holding Corporation Announces Chief Executive Officer Changes, Effective on September 1, 2023

Broncus Holding Corporation Announces Re-Designation of Guowei Zhan from an Executive Director to Non-Executive Director, Effective September 1, 2023

Broncus Holding Corporation to Report First Half, 2023 Results on Aug 29, 2023

Broncus Holding Corporation Completes the First Case of Registered Clinical Trials of Its Targeted Lung Denervation Radiofrequency Ablation System

Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?

Consensus estimates of losses per share improve by 48%

Consensus revenue estimates fall by 36%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Less than half of directors are independent

Broncus Holding Corporation Announces Zhejiang Medical Products Administration Approves Disposable Nebulizing Micro-Catheter for Endoscope for Marketing in China

Consensus forecasts updated

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

First half 2022 earnings released: US$0.03 loss per share (vs US$0.19 loss in 1H 2021)

Broncus Holding Corporation Announces Board and Executive Changes

Broncus Holding Corporation to Report First Half, 2022 Results on Aug 30, 2022

Consensus EPS estimates fall by 16%

Broncus Holding Corporation Completes Surgeries on the First Group of Patients Using Its InterVapor, the Thermal Vapor Treatment System, After Approved for Marketing in China

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Broncus Holding Corporation, Annual General Meeting, May 13, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Broncus Holding Corporation Announces Resignation of Wen Hao Wang as Chief Financial Officer

Non Executive Director recently bought HK$390k worth of stock

Broncus Holding Corporation announces Enrollment for Registered Clinical Trials Successfully Completed for RF-II in China

Broncus Holding Corporation has completed an IPO in the amount of HKD 1.670939 billion.

Less than half of directors are independent

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin